These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 15625434

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. [Evolution of a case of tyrosinemia type I treated with NTBC].
    Ros Viladoms J, Vilaseca Buscà MA, Lambruschini Ferri N, Mas Comas A, González Pascual E, Holme E.
    An Esp Pediatr; 2001 Mar; 54(3):305-9. PubMed ID: 11262262
    [Abstract] [Full Text] [Related]

  • 3. Tyrosinemia type I treated by NTBC: how does AFP predict liver cancer?
    Koelink CJ, van Hasselt P, van der Ploeg A, van den Heuvel-Eibrink MM, Wijburg FA, Bijleveld CM, van Spronsen FJ.
    Mol Genet Metab; 2006 Dec; 89(4):310-5. PubMed ID: 17008115
    [Abstract] [Full Text] [Related]

  • 4. Discontinuation of NTBC after liver transplantation in tyrosinemia type 1.
    Kurihara K, Toyoda H, Amoano K, Inoue M, Uchida K, Sakurai H, Hayashi A, Hirayama M.
    Pediatr Int; 2018 Nov; 60(11):1039-1041. PubMed ID: 30375135
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Hepatocellular carcinoma in tyrosinemia type 1 without clear increase of AFP.
    van Ginkel WG, Gouw AS, van der Jagt EJ, de Jong KP, Verkade HJ, van Spronsen FJ.
    Pediatrics; 2015 Mar; 135(3):e749-52. PubMed ID: 25667247
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Tyrosinemia type 1: metastatic hepatoblastoma with a favorable outcome.
    Nobili V, Jenkner A, Francalanci P, Castellano A, Holme E, Callea F, Dionisi-Vici C.
    Pediatrics; 2010 Jul; 126(1):e235-8. PubMed ID: 20547648
    [Abstract] [Full Text] [Related]

  • 9. Experience of nitisinone for the pharmacological treatment of hereditary tyrosinaemia type 1.
    Santra S, Baumann U.
    Expert Opin Pharmacother; 2008 May; 9(7):1229-36. PubMed ID: 18422479
    [Abstract] [Full Text] [Related]

  • 10. [Clinical follow up of Chilean patients with tyrosinemia type 1 treated with 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-ciclohexanedione (NTBC)].
    Raimann E, Cornejo V, Arias C, Cabello JF, Castro G, Fernández E, de la Parra A.
    Rev Med Chil; 2012 Feb; 140(2):169-75. PubMed ID: 22739945
    [Abstract] [Full Text] [Related]

  • 11. The fate of tyrosinaemic Hungarian patients before the NTBC aera.
    László A, Rózsa M, Sallay E, Tiszlavicz L, Janovszky A, Várkonyi A, Karg E, Wittmann G, Túri S, Ugarte M.
    Ideggyogy Sz; 2013 Nov 30; 66(11-12):415-9. PubMed ID: 24555242
    [Abstract] [Full Text] [Related]

  • 12. Reversibility of cirrhotic regenerative liver nodules upon NTBC treatment in a child with tyrosinaemia type I.
    Crone J, Möslinger D, Bodamer OA, Schima W, Huber WD, Holme E, Stöckler Ipsiroglu S.
    Acta Paediatr; 2003 May 30; 92(5):625-8. PubMed ID: 12839296
    [Abstract] [Full Text] [Related]

  • 13. Hepatocellular carcinoma requiring liver transplantation in hereditary tyrosinemia type 1 despite nitisinone therapy and α1-fetoprotein normalization.
    Bhushan S, Noble C, Balouch F, Lewindon P, Lampe G, Hodgkinson P, McGill J, Ee L.
    Pediatr Transplant; 2022 Nov 30; 26(7):e14334. PubMed ID: 35698261
    [Abstract] [Full Text] [Related]

  • 14. Hereditary tyrosinemia type 1 in Turkey: twenty year single-center experience.
    Zeybek AC, Kiykim E, Soyucen E, Cansever S, Altay S, Zubarioglu T, Erkan T, Aydin A.
    Pediatr Int; 2015 Apr 30; 57(2):281-9. PubMed ID: 25223216
    [Abstract] [Full Text] [Related]

  • 15. HCC prevalence and histopathological findings in liver explants of patients with hereditary tyrosinemia type 1.
    Seda Neto J, Leite KM, Porta A, Fonseca EA, Feier FH, Pugliese R, Miura IK, Chapchap P, Porta G.
    Pediatr Blood Cancer; 2014 Sep 30; 61(9):1584-9. PubMed ID: 24852359
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Pharmacological and clinical profile of nitisinone (Orfadin(®) Capsules): a therapeutic agent for hereditary tyrosinemia type 1].
    Minoura H, Iwai M, Taniuchi Y, Katashima M, Takahashi H.
    Nihon Yakurigaku Zasshi; 2015 Dec 30; 146(6):342-8. PubMed ID: 26657126
    [No Abstract] [Full Text] [Related]

  • 18. Hereditary tyrosinaemia type I: from basics to progress in treatment.
    Pitkänen ST, Salo MK, Heikinheimo M.
    Ann Med; 2000 Nov 30; 32(8):530-8. PubMed ID: 11127930
    [Abstract] [Full Text] [Related]

  • 19. Nitisinone in the treatment of hereditary tyrosinaemia type 1.
    McKiernan PJ.
    Drugs; 2006 Nov 30; 66(6):743-50. PubMed ID: 16706549
    [Abstract] [Full Text] [Related]

  • 20. Nontransplant treatment of tyrosinemia.
    Holme E, Lindstedt S.
    Clin Liver Dis; 2000 Nov 30; 4(4):805-14. PubMed ID: 11232358
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.